Review Article

Impacts of Membrane Biophysics in Alzheimer’s Disease: From Amyloid Precursor Protein Processing to Aβ Peptide-Induced Membrane Changes

Sholpan Askarova, Xiaoguang Yang, and James C.-M. Lee

Department of Biological Engineering, University of Missouri, Columbia, MO 65211, USA

Correspondence should be addressed to James C.-M. Lee, leejam@missouri.edu

Received 27 October 2010; Revised 30 December 2010; Accepted 21 January 2011

An increasing amount of evidence supports the notion that cytotoxic effects of amyloid-β peptide (Aβ), the main constituent of senile plaques in Alzheimer’s disease (AD), are strongly associated with its ability to interact with membranes of neurons and other cerebral cells. Aβ is derived from amylloidogenic cleavage of amyloid precursor protein (AβPP) by β- and γ-secretases. In the nonamyloidogenic pathway, AβPP is cleaved by α-secretases. These two pathways compete with each other, and enhancing the non-amyloidogenic pathway has been suggested as a potential pharmacological approach for the treatment of AD. Since AβPP, α-, β-, and γ-secretases are membrane-associated proteins, AβPP processing and Aβ toxicity should prove to provide new therapeutic strategies for prevention and treatment of AD.

1. Introduction

The senile plaque composed of neurotoxic amyloid-β peptide (Aβ) is a pathologic characteristic of Alzheimer’s disease (AD) [1–6]. Aβ is derived from the cleavage of a type I membrane protein, (AβPP), by β- and γ-secretases [7]. Alternatively, AβPP can be cleaved by α-secretase to produce a neurotrophic, neuroprotective α-secretase-cleaved soluble AβPP (sAβPPα) through a nonamyloidogenic pathway [8]. These two pathways compete with each other, and increasing sAβPPα has been suggested as a potential therapy for AD [9]. The cleavage of AβPP by β-secretase (BACE), the primary step to produce Aβ [10, 11], occurs mainly in lipid rafts, which are highly ordered membrane microdomains enriched in cholesterol, sphingolipids and saturated phospholipids [12–17]. On the other hand, the activity of α-secretases is favored in nonraft domains [18]. Therefore, AβPP processing can be altered by manipulating membrane lipid composition, such as removal of cholesterol and sphingolipids [19–22]. Since AβPP, α-, β-, and γ-secretases are membrane proteins, AβPP processing can be also affected by the biophysical membrane properties such as membrane fluidity and molecular order [19–26].

Amyloidogenic cleavage of the AβPP leads to the production of Aβ peptides of different length [27]. An increasing amount of evidence supports the notion that cytotoxic effects of Aβ are strongly associated with its ability to interact with membranes of neurons and other cerebral cells, astrocytes, microglial, and cerebral endothelial cells. Aβ peptides in different forms can directly bind to membrane receptors and trigger downstream signaling pathways. Moreover, there is evidence that Aβ1–41 oligomers can accelerate the amyloidogenic processing of AβPP by changing membrane physical properties and interacting with lipid raft-related ganglioside GM-1 [25]. Membrane properties and composition, and the presence of metal ions,
in turn, play critical roles in Aβ cytotoxicity associated with its conformational changes, aggregation into oligomers and fibrils, and ability to interact with membrane molecules [34–40].

In this paper, we summarize the effects of membrane composition and properties on AβPP processing and interactions of physiologically relevant Aβ1–40 and Aβ1–42, with membranes studied in model systems, cell cultures, and in vivo. Understanding the mechanisms leading to changes in a membrane’s biophysics and how they cause changes in AβPP processing and Aβ toxicity should provide insights into new therapeutic strategies for prevention and treatment of AD.

2. Role of Physical Membrane Properties in AβPP Processing

2.1. Cholesterol on Physical Properties of Membranes and AβPP Processing. Cholesterol is an essential component of the cellular membrane and plays a vital role in the regulation of membrane functions. Distribution of cholesterol within the plasma membrane is not even: the highest level of free cholesterol inside the plasma membrane is found in cytoskeletal bilayer leaflet [41, 42]. The exosomal leaflet contains substantially less cholesterol, and it is mostly condensed in lipid rafts, which are more tightly packed than nonlipid raft domains due to intermolecular hydrogen bonding involving sphingolipid and cholesterol [43]. This asymmetric distribution of cholesterol is altered by aging: it is significantly increased in exosomal leaflet with increasing age [42, 44]. Membrane cholesterol levels can also be modulated by specific inhibitors of the cellular biosynthesis such as statins (3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA) inhibitors), or it can be selectively extracted from plasma membrane by methyl-β-cyclodextrin (MβCD) [41]. The percentage of cholesterol in phospholipid bilayers affects many biophysical parameters of lipid bilayers, such as thickness, thermomechanical properties, molecular packing, conformational freedom of phospholipid acyl chains and water, molecular oxygen permeability, membrane hydrophobicity, membrane excitability in neurons, internal dipolar potential, and membrane fluidity [45–51].

It has been shown that intracellular cholesterol homeostasis regulates AβPP processing [52]. A model of membrane compartmentalization has been suggested for AβPP present in two cellular pools, one associated with the cholesterol-enriched lipid rafts, where Aβ is generated, and another outside of rafts (i.e., nonraft domains), where α-cleavage occurs [13]. It has been reported that membrane cholesterol depletion decreased the content of AβPP in cholesterol and sphingolipid-enriched membrane microdomains and subsequently inhibited the amyloidogenic pathway to produce Aβ [19, 53]. In contrast, cholesterol accumulation in Niemann Pick type C (NPC) model cells has been shown to shift AβPP localization to lipid rafts [54]. Exposure of cholesterol to astrocytes, primary neurons, and glial cultures inhibited the secretion of sAPPα and reduced cell viability [55–57]. It has been demonstrated that cholesterol decreased the secretion of sAPPα by interfering with AβPP maturation and inhibiting glycosylation of the protein [56]. Furthermore, some studies showed that cholesterol levels in the membranes were positively correlated with β-secretase activity [58], while lovastatin enhanced the α-secretase activity [55].

The results of another study showed that the cholesterol transport inhibitor, U18666a, increased sAβPPα secretion and intracellular AβPPα levels and reduced secretion of Aβ1–40 in N2aAPP “Swedish” cells [59]. Inhibition of intracellular cholesterol transport also altered presenilin localization and AβPP processing in neuronal cells [60]. Similarly, inhibition of Acyl-coenzyme A:cholesterol acyltransferase (ACAT) modulated AβPP trafficking and reversed diffuse brain amyloid pathology in aged AβPP transgenic mice [61–63]. Nevertheless, lowering cholesterol by treatment with statins was found to reduce [13, 21, 64] or enhance Aβ generation, depending on the condition of the study [65].

One possible explanation for the controversial results is that moderate reduction in cholesterol is associated with a disorganization of detergent-resistant membranes (DRMs) or lipid rafts, allowing more β-site AβPP cleaving enzyme (BACE) to contact AβPP and resulting in increased Aβ generation, whereas a strong reduction of cholesterol inhibits the activities of BACE and y-secretase, resulting in a decrease in Aβ generation [14]. On the other hand, in the low-dose statin treatment conditions [65], enchanted Aβ production could be a result of feedback upregulation of HMG-CoA reductase and increased cholesterol level.

Consistent with the membrane compartmentalization model, cellular cholesterol depletion results in an increase in membrane fluidity, a parameter which characterizes an average lateral motion of phospholipid molecules within the lipid bilayer [19, 66–69]. On the other hand, an increase in membrane fluidity has been demonstrated to shift AβPP processing to nonamyloidogenic cleavage by α-secretase [54–56, 65–68]. It has been reported that the removal of cholesterol with methyl-β-cyclodextrin or treatment with lovastatin increased membrane fluidity, which resulted in higher expression of the α-secretase and impaired internalization of AβPP [19]. At the same time, cholesterol enrichment has been shown to reduce membrane fluidity [70, 71]. Cholesterol enrichment that impeded membrane fluidity may lower sAβPPα production by hindering the interaction of the substrate with its proteases [72]. Interestingly, substitution of cholesterol by the steroid 4-cholene-3-one induces minor change in membrane fluidity and reduces sAβPPα secretion, whereas substitution of cholesterol by lanosterol increases membrane fluidity and sAβPPα secretion [19]. These results suggest reversible effects of cholesterol on the α-secretase activity depending on membrane fluidity.

Many studies support the notion that Aβ production occurs in endosomes [22, 73–77]. Since AβPP is a transmembrane protein, its internalization from the plasma membrane is regulated by key regulators of endocytosis, such as Rab5, and this process has been found to enhance AβPP cleavage by β-secretase leading to increased Aβ levels [78]. In contrast, AβPP, lacking its cytoplasmic internalization motif, can
accumulate at the plasma membrane and undergo cleavage by α-secretase [10, 11]. Cholesterol has been demonstrated to increase clathrin-dependent AβPP endocytosis in a dose-dependent and linear manner [79]. There were also studies demonstrating that alterations in cholesterol transport from late endocytic organelles to the endoplasmic reticulum had important consequences for both AβPP processing and the localization of γ-secretase-associated presenilins [60]. It has been suggested that cholesterol increase in AD could be responsible for the enhanced internalization of clathrin-, dynamin2-, Eps15-, and Rab5-dependent endocytosis of AβPP and the ensuing overproduction of Aβ [79]. Alternatively, AβPP internalization could be reduced by lowering cholesterol, which leads to an increase in membrane fluidity, AβPP accumulation on the cell surface, and increased sAβPPα secretion [19].

2.2. Fatty Acids on Membrane Physical Properties and AβPP Processing. Fatty acids are other essential components of the cellular membranes. They are important ingredients in various dietary sources and play a central role in the normal development and function of the brain [80–83]. For example, long-chain polyunsaturated fatty acids (PUFAs) of the ω-6 and ω-3 series, the major polyunsaturated fatty acids in the central nervous system [84], are essential for prenatal brain development and normal brain functions [83, 85, 86]. Animals specifically deficient in dietary ω-3 fatty acids have been demonstrated to have reduced visual acuity and impaired learning ability [86, 87]. Diets enriched in long-chain ω-3 PUFA (DHA) have been shown to modulate gene expression for brain function, improve synaptic and neurotransmitter functions of neurons, enhance learning and memory performances, and display neuroprotective properties [86, 88–90]. Arachidonic acid (AA), another abundant fatty acid in the brain, is a second messenger [91] and a precursor for the synthesis of eicosanoids [92]. The presence of PUFAs in neuronal cells influences cellular function both directly, through effects on membrane properties, and indirectly by acting as precursors for lipid-derived messengers [93, 94].

In fact, the disturbed metabolism of fatty acids is associated with AD [95]. For instance, lower levels of DHA have been reported in serum samples taken from AD patient [96], while greater consumption of DHA has significantly reduced the likelihood of developing AD [97]. Dietary ω-3 PUFA depletion has been shown to activate caspases and decrease NMDA receptors in the brain of a transgenic mouse model of AD [98]. DHA and curcumin have been shown to suppress Aβ-induced phosphorylation of tau tangles and the inactivation of insulin receptors in primary rat neurons [99]. Recently, reduced expression of the neuronal sortilin-related receptor SorLA/LR11 (LR11), a sorting protein that regulates APP trafficking to β- and γ-secretases, was identified as a probable genetic risk factor for late-onset Alzheimer’s disease [100]. DHA, in turn, has been found to increase LR11 expression in primary rat neurons, human neuronal line, and aged nontransgenic and DHA-depleted APPsw AD transgenic mice [101]. In 15-month-old AβPP/presenilin-1 mice, DHA supplementation improved spatial memory, decreased Aβ deposition, and slightly increased relative cerebral blood volume, indicating that a DHA-enriched diet can diminish AD-like pathology [102].

Dietary fatty acids may integrate into cell membranes to change their physical properties and subsequently alter cell functions. The ability of fatty acids to modulate membrane properties and functions [90, 94, 103–109] depends both on the saturation degree of the fatty acids and the trans/cis ratio of the unsaturated fatty acids [110–113]. For example, diets enriched in unsaturated PUFAs, DHA, and AA have been shown to increase membrane fluidity of neurons and other cells [71, 89, 114, 115]. DHA has been also capable of counteracting cholesterol-induced decreases in platelet membrane fluidity and modulating platelet hyperaggregation [71]. Similarly, cis-polysaturated linolenic, α-linolenic, and eicosatrienoic fatty acids increased membrane fluidity [110]. In contrast, membrane incorporation of saturated acids led to decreased membrane fluidity [109, 112, 116]. PUFAs have also been shown to affect many other membrane properties, such as molecular order, compressibility, permeability, fusion, and protein activity [117, 118].

Since AβPP, α-, β-, and γ-secretases are membrane protein molecules, AβPP processing can be altered by manipulating the membrane lipid composition. It was mentioned before that an increase in membrane fluidity has resulted in an increase in nonamyloidogenic cleavage by α-secretase to produce sAβPPα [19, 25]. At the same time, enrichment of cell membranes with PUFAs increases membrane fluidity and, consequently, promotes nonamyloidogenic processing of AβPP [113]. It has been shown that a typical Western diet (with 40% saturated fatty acids and 1% of cholesterol) fed to transgenic AβPP/PS1 mice increased Aβ, while diets supplemented with DHA decreased Aβ levels compared to regular diet [119]. Similarly, DHA has been shown to decrease the amount of vascular Aβ deposition [120] and reduce cortical Aβ burden [121] in the aged Alzheimer mouse model. In this model, DHA modulated AβPP processing by decreasing both α- and β-AβPP C-terminal fragment products and full-length AβPP [121]. DHA has also been shown to stimulate nonamyloidogenic AβPP processing resulting in reduced Aβ levels in cellular models of Alzheimer’s disease [122]. At the same time, the study of the effects of fatty acids on cell membrane fluidity and sAβPPα secretion in relation to degrees of unsaturation has suggested that not all unsaturated fatty acids, but only those with 4 or more double bonds, such as arachidonic acid (20:4), eicosapentaenoic acid (20:5), and DHA (22:6), increased membrane fluidity and led to an increase in sAβPPα secretion, while oleic acid (18:1), linoleic acid (18:2), and α-linolenic acid (18:3) did not [113]. Moreover, the results of another experiment have indicated that treatment of PSwt-1 cells with oleic acid and linoleic acid increased γ-secretase activity and Aβ production [123].

2.3. Phospholipases A2 on Membrane Physical Properties and AβPP Processing. Phospholipases A2 (PLA2s) are ubiquitously distributed in mammalian cell enzymes that catalyze
the hydrolysis of fatty acids from sn-2 position of phospholipids. PLA₂s are classified into three major families: calcium-dependent cytosolic PLA₂ (cPLA₂), secretory PLA₂ (sPLA₂), and calcium-independent PLA₂ (iPLA₂). These enzymes are responsible for maintenance of phospholipid homeostasis in the cell membrane. They are also important in production of lipid mediators, such as arachidonic acid. Activation of PLA₂s has been implicated in diverse cellular responses such as mitogenesis, differentiation, inflammation, and cytotoxicity, and changes in PLA₂s' activities occur in many neurodegenerative diseases, including AD [124–136].

It has been shown that immunoreactivity of cPLA₂ (group IIA and IVA) increased in reactive astrocytes in severe AD patient brains [124–126]. Upregulations of sPLA₂-IIA and PLA₂-IVA were reported in the hippocampus of AD patients [126, 137, 138]. The levels of activated cPLA₂-IVA were also increased in the hippocampus of hAβPP mice [138]. Furthermore, Aβ has been shown to activate cPLA₂ in primary rat and mouse brain endothelial cells, astrocytes, cortical neurons, and in PC12 cells [139–143]. Contradictory, both increased and reduced PLA₂ activity has been reported in platelets of AD patients [144, 145]. At the same time, PLA₂ activity was significantly decreased in the parietal and, to a lesser degree, in frontal cortex of AD brains. Lower PLA₂ activity correlated significantly with an earlier onset of the disease, higher counts of neurofibrillary tangles and senile plaques and an earlier age of death, indicating a relationship between abnormally low PLA₂ activity and a more severe form of the illness [146].

PLA₂s play key roles in modulation of membrane properties under pathological and physiological conditions. For instance, in immortalized rat astrocytes (DITNC cells), cPLA₂ mediated the Aβ-induced membrane molecular order increase (biophysical parameter which characterizes molecular packing of lipids and water in lipid bilayers) [147]. In primary rat cortical astrocytes, ROS induced by menadione, a redox active agent, also altered astrocyte's membrane activation has been shown to a

3. Role of Membrane Physical Properties in Aβ-Membrane Interaction and Aβ Cytotoxicity

3.1. Aβ-Membrane Interactions Studied in Membrane Models and in Cell Cultures. Cleavage of AβPP leads to the production of Aβ peptides of different length, of which Aβ₁₋₄₀ is the major species and Aβ₁₋₄₂ is the most fibrillogenic and toxic component in AD plaques [27]. Numerous studies have demonstrated direct interaction of Aβ₁₋₄₀ and Aβ₁₋₄₂ with components of the plasma membrane, which consequentially disrupts the membrane properties [28–33, 158–160]. There are several suggested types of Aβ-membrane interactions. Aβ peptide can be retained in a membrane upon AβPP cleavage, thus being prevented against release and aggregation [161]. It also can be released as soluble monomers into the extracellular environment and then be removed [161, 162]. On the other hand, Aβ can reinsert into a membrane and form ion-conducting pores or bind to a membrane surface by undergoing accelerated aggregation and form nonspecific structures, which causes thinning and deformation to the membrane [161, 163–166].

Aβ₁₋₄₂ has been shown to reduce membrane fluidity and accelerate the amyloidogenic processing of AβPP [25, 33, 167–172]. In vivo, a decrease in membrane fluidity of synaptosomes isolated from frontal and hypothalamic neurons of 3-month-old mice, administrated with Aβ, has been demonstrated [171]. By using in situ atomic force microscopy and fluorescence spectroscopy, randomly structured Aβ₁₋₄₂ has been reported to decrease membrane fluidity of planar bilayers composed of total brain lipids, and this effect is cholesterol-content dependent: the most dramatic effect has been seen for cholesterol-enriched samples [168], DPH (1,6-diphenyl-1,3,5-hexatriene) fluorescence study has shown a similar effect of Aβ₁₋₄₀ on membrane fluidity of unilamellar liposomes with a strong correlation to Aβ aggregation state and pH [170]. It has been reported that unaggregated peptides and pH 7 do not affect membrane fluidity, while aggregated Aβ at pH 6 or 7 decreased membrane fluidity in a time- and dose-dependent manner [170]. Studies of SH-SY5Y human neuroblastoma cells have shown some contradictory results. In this observation, Aβ₁₋₄₂ monomers increased fluidity of cell membranes, and Aβ-Aluminium complex promoted even a greater effect [172]. Differences in effects of Aβ on fluidity could result from the tissue source and preparation, whether Aβ is soluble or aggregated, and the age of the organism. The differences in effects of Aβ on fluidity could also be the result of differences in the location of the fluorescent probes in the membrane environment and the lifetime of the fluorescent probes.

The fluorescence microscopy of a membrane with the environmentally sensitive probe Laurdan has demonstrated the ability of Aβ₁₋₄₂ oligomers to affect the membrane molecular order [147, 173, 174]. It has been shown that an interaction of Aβ₁₋₄₂ with artificial membranes made them molecularly disordered (more water molecules were
partitioned into the membrane core) due most likely to the insertion of the peptide into the bilayer and the direct alteration of membrane lipid packing. In the same study, the effect of Aβ1-42 oligomers on immortalized rat astrocytes (DITNC cells) membranes was opposite. DITNC membranes become more molecularly ordered upon incubation with Aβ in a time-dependent manner, and it was consistent with activation of cPLA2. At the same time, in the presence of NADPH oxidase inhibitor, the membranes of the cells remained molecularly disordered. These results suggested an indirect effect of Aβ through the signaling pathway involving NADPH oxidase and cPLA2 [147].

The study of the interaction of Aβ1-42 with unilamellar lipid vesicles has demonstrated increased vesicle fusion and a thinning of the lipid bilayer and enhancing of these effects at pH 7 and at a high Aβ/lipid ratio [175]. The micropipette manipulation of giant unilamellar vesicles has shown the ability of Aβ1-42 to affect the membrane lysis tension depending on artificial membrane lipid composition. It has been found that neither Aβ1-42 nor Aβ1-40 changed mechanical properties of glycerophospholipid-cholesterol vesicles, while partial substitutions of cholesterol with β-hydroxycholesterol that contained additional dipole of oxysterol led to a dramatic reduction of the lysis tension upon Aβ treatment. The results of this experiment strongly suggest that a negative bilayer surface charge is required for Aβ-membrane interaction [176].

The Aβ-membrane interaction may also be followed by the incorporation of Aβ into the membranes and formation of cation-selective channels, which lead to alteration of membrane permeability and electrical conductance [31, 177–186]. The study of the effects of soluble Aβ1-42 oligomers on planar lipid and tethered lipid bilayers has indicated that Aβ oligomers were inserted into the hydrophobic core of the bilayer, affecting both membrane leaflets and significantly increasing membrane ion current [31, 178]. It has been demonstrated that Aβ-induced ion conductance was different from ion transfer through water-filled pores and depended on peptide concentration and membrane lipid composition [178]. Similarly, Aβ1-40 caused a dose-dependent increase in the Na+, Ca2+, and K+ influx in the lumen of liposomes formed from the acidic phospholipids but did not change cation conductance in a case of liposomes formed from the neutral phospholipids [179]. There was also evidence that Aβ induced an increase in membrane conductance, which was dependent on the area compressibility of the lipid bilayer. Membranes with a large area compressibility modulus were almost insensitive to Aβ1-42 oligomers, while membranes formed from soft, highly compressible lipids were very sensitive to the presence of oligomers [31].

In vitro, after Aβ1-42 treatment, the membranes of human neuronal hNT cells and neuron-like differentiated PC12 cells depolarized and exhibited enhanced membrane permeability [183, 186]. Patch-clamp studies of a cell line derived from hypothalamic gonadotrophin-releasing hormone GnRH neurons have demonstrated spontaneous formation of Zn2+-sensitive channel pores upon Aβ1-40 monomers treatment [184]. Similarly, Aβ1-40 aggregates induced perforation of hippocampal neuronal synapses, causing an increase in membrane conductance, intracellular calcium, and ethidium bromide influx [185]. It has been suggested that Aβ-induced membrane depolarization and increased ions influx in neurons was not just due to forming of cation-selective pores but rather was a consequence of events resulting from downstream pathways with involvement of metabotropic glutamate receptor and G-proteins [186].

3.2 Membrane-Associated Conformational Modifications and Aggregation of Aβ. In a previous section, we discussed the ability of Aβ to alter biophysical properties of membranes and the dependence of these processes on membrane environment. These studies suggest that membrane property and composition, in turn, play a critical role in conformational changes and aggregation of Aβ. The aggregation of Aβ is a complicated multistep process consisting of several phases: monomers → soluble oligomers (clusters of small numbers of peptide molecules without a fibrillar structure) → protofibrils (aggregates of isolated or clustered spherical beads made up of ~20 molecules with β-sheet structure) → mature fibrils [187]. Although the mechanism which initiates Aβ aggregation is not fully understood, it has been shown to be modulated by several factors, including concentrations of monomers and their conformational transitions, sequential changes in the Aβ primary structure, and interactions with metal ions and membrane molecules [35, 37, 40, 169].

In vitro studies have demonstrated that Aβ monomers can exist in three major conformation forms: α-helix, β-sheet, or random coil depending on physical properties and chemical composition of the environment [188, 189]. Since the toxic Aβ mostly consists of β-sheets, even though the original hydrophobic component of Aβ is a part of a transmembrane α-helix of AβPP, the conformational transition of Aβ from α-helix or random coil to β-sheet is most likely the very first step in the formation of oligomers and fibrils [190]. Multidimensional NMR spectroscopy and circular dichroism (CD) studies have demonstrated that alterations in the membrane structure and biophysics can trigger the conversion of soluble α-helical monomeric Aβ1-40 into the oligomeric β-sheet conformation [161, 189]. It has been shown that, in an ordered membrane system, Aβ adopted a single α-helical confirmation, while in disordered micelles Aβ rather adopted soluble β-sheet oligomeric conformation [189]. At the same time, study of the neutral and negatively charged bilayers showed an increase in β-sheet content as the negative charge on the lipid membrane increased [161, 191].

In situ atomic force microscopy and total internal reflection fluorescence microscopy studies have indicated that the size and the shape of Aβ1-40 and Aβ1-42 aggregates, as well as the kinetics of their formation, depended on the physicochemical nature of the surface [192, 193]. For example, on hydrophilic surfaces (mica) Aβ1-40 formed particulate, pseudomolecular aggregates, while on hydrophobic surfaces (graphite) Aβ formed uniform, elongated sheets with dimensions consistent with the dimensions of β-sheets. The results of this study suggested that Aβ fibril formation may be driven by interactions at the interface of aqueous
solutions and hydrophobic substrates, which occurs in membranes and lipoprotein particles \textit{in vivo} [192]. Similarly, Aβ\textsubscript{1–40} fibril growth was especially prominent on chemically modified negatively charged quartz surfaces, while no fibril formation was observed on the positively charged surfaces [193].

Numerous \textit{in vitro} and \textit{in vivo} studies have demonstrated that lipid bilayer composition, as well as membrane-associated proteins, can regulate Aβ aggregation in both enhancement and inhibition manner [37–40]. It has been suggested that binding of Aβ to the ganglioside-containing membranes can induce a structural transition from random coil to β-sheet in Aβ\textsubscript{40/42} and accelerate fibril formation [194–196]. Electron microscopy studies have demonstrated that interaction of Aβ\textsubscript{40/42} with plasma, lysosomal, and endosomal membranes accelerated fibrillogenesis of Aβ, while the presence of Golgi membranes hindered the process [169].

4. Conclusion

An increasing amount of evidence demonstrates that a lot of cellular processes in AD are intimately associated with physical properties and organization of membranes. The primary step in Aβ accumulation, the amyloidogenic cleavage of AβPP, is affected by the membrane properties such as membrane fluidity and molecular order and can be modulated by removal of cholesterol and manipulation of membrane lipid composition. Aβ-membranes interaction, in turn, affects biophysical membrane properties and accelerates the amyloidogenic processing of AβPP. Aβ has been reported to reduce membrane fluidity, affect molecular order and membrane lysis tension, induce thinning of the lipid bilayer, and increase membrane conductance. Aβ can also indirectly affect membrane properties by binding to membrane receptors and triggering downstream signaling pathways leading to oxidative stress and inflammation. On the other hand, the ability of Aβ to interact with membranes of neurons and other cerebral cells depends on physical properties and organization of membranes, such as cholesterol content, lipid composition and Aβ/lipid ratio, pH, the presence of metal ions, and bilayer surface charge. Membrane properties and composition play critical roles in Aβ cytotoxicity associated with its conformational changes and aggregation state as well. Therefore, understanding how membrane properties and organization are related to cellular pathways in AD should prove to provide insights into the mechanisms of the pathogenesis in AD.

References

[1] D. W. Dickson, “Microglia in Alzheimer’s disease and transgenic models: how close the fit?” American Journal of Pathology, vol. 154, no. 6, pp. 1627–1631, 1999.
[2] S. A. Frautschy, F. Yang, M. Irrizarry et al., “Microglial response to amyloid plaques in APPsw transgenic mice,” American Journal of Pathology, vol. 152, no. 1, pp. 307–317, 1998.
[3] P. L. McGeer, S. Itagaki, H. Tago, and E. G. McGeer, “Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR,” Neuroscience Letters, vol. 79, no. 1–2, pp. 195–200, 1987.
[4] L. S. Perlmutter, E. Barron, and H. C. Chui, “Morphologic association between microglia and senile plaque amyloid in Alzheimer’s disease,” Neuroscience Letters, vol. 119, no. 1, pp. 32–36, 1990.
[5] D. J. Selkoe, “The origins of Alzheimer disease: a is for amyloid,” Journal of the American Medical Association, vol. 283, no. 12, pp. 1615–1617, 2000.
[6] M. Stalder, A. Phinney, A. Probst, B. Sommer, M. Staufenbiel, and M. Jucker, “Association of microglia with amyloid plaques in brains of APP23 transgenic mice,” American Journal of Pathology, vol. 154, no. 6, pp. 1673–1684, 1999.
[7] R. Vassar, “BACE1: the β-secretase enzyme in Alzheimer’s disease,” Journal of Molecular Neuroscience, vol. 23, no. 1–2, pp. 105–113, 2004.
[8] E. Thornton, R. Vink, P. C. Blumbergs, and C. Van Den Heuvel, “Soluble amyloid precursor protein α reduces neuronal injury and improves functional outcome following diffuse traumatic brain injury in rats,” Brain Research, vol. 1094, no. 1, pp. 38–46, 2006.
[9] H. Cheng, K. S. Vetrivel, P. Gong, X. Meckler, A. Parent, and G. Thinakaran, “Mechanisms of disease: new therapeutic strategies for Alzheimer’s disease—targeting APP processing in lipid rafts,” Nature Clinical Practice Neurology, vol. 3, no. 7, pp. 374–382, 2007.
[10] C. Haass, A. Y. Hung, M. G. Schlossmacher, D. B. Teplow, and D. J. Selkoe, “β-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms,” The Journal of Biological Chemistry, vol. 268, no. 5, pp. 3021–3024, 1993.
[11] E. H. Koo and S. L. Squazzo, “Evidence that production and release of amyloid β-protein involves the endocytic pathway,” The Journal of Biological Chemistry, vol. 269, no. 26, pp. 17386–17389, 1994.
[12] J. M. Cordy, I. Hussain, C. Dingwall, N. M. Hooper, and A. J. Turner, “Exclusively targeting β-secretase to lipid rafts by GPI-anchor addition up-regulates β-site processing of the amyloid precursor protein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 20, pp. 11735–11740, 2003.
[13] R. Eshelalt, P. Keller, C. Haass, C. Thiele, and K. Simons, “Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts,” Journal of Cell Biology, vol. 160, no. 1, pp. 113–123, 2003.
[14] C. Kaether and C. Haass, “A lipid boundary separates APP and secretases and limits amyloid β-peptide generation,” Journal of Cell Biology, vol. 167, no. 5, pp. 809–812, 2004.
[15] L. Marlow, M. Cain, M. A. Pappolla, and K. Sambamurti, “β-Secretase Processing of the Alzheimer’s Amyloid Protein Precursor (APP),” Journal of Molecular Neuroscience, vol. 20, no. 3, pp. 233–239, 2003.
[16] H. Tun, L. Marlow, I. Pinnix, R. Kinsey, and K. Sambamurti, “Lipid rafts play an important role in Aβ biogenesis by regulating the β-secretase pathway,” Journal of Molecular Neuroscience, vol. 19, no. 1–2, pp. 31–35, 2002.
[17] K. S. Vetrivel, H. Cheng, W. Lin et al., “Association of γ-secretase with lipid rafts in post-golgi and endosomal membranes,” The Journal of Biological Chemistry, vol. 279, no. 43, pp. 44945–44954, 2004.
[18] P. C. Reid, Y. Urano, T. Kodama, and T. Hamakubo, "Alzheimer’s disease: cholesterol, membrane rafts, isotopomers and statins," Journal of Cellular and Molecular Medicine, vol. 11, no. 3, pp. 383–392, 2007.

[19] E. Kojro, G. Gimpl, S. Lammich, W. März, and F. Fahrenholz, "Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10," Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 10, pp. 5815–5820, 2001.

[20] N. Sawamura, M. Ko, W. Yu et al., "Modulation of amyloid precursor protein cleavage by cellular sphingolipids," The Journal of Biological Chemistry, vol. 279, no. 12, pp. 11984–11991, 2004.

[21] M. Simons, P. Keller, B. De Strooper, K. Beyreuther, C. G. Dotti, and K. Simons, "Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons," Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 11, pp. 6460–6464, 1998.

[22] C. A. F. Arnim, B. von Einem, P. Weber et al., "Impact of cholesterol level upon APP and BACE proximity and APP cleavage," Biochemical and Biophysical Research Communications, vol. 370, no. 2, pp. 207–212, 2008.

[23] H. W. Cho, J. H. Kim, S. Choi, and H. J. Kim, "Phospholipase A2 is involved in muscarinic receptor-mediated sAPPα release independently of cyclooxygenase or lipoxygenase activity in SH-SYSY cells," Neuroscience Letters, vol. 397, no. 3, pp. 214–218, 2006.

[24] A. B. Clement, G. Gimpl, and C. Behl, "Oxidative stress resistance in hippocampal cells is associated with altered membrane fluidity and enhanced nonamyloidogenic cleavage of endogenous amyloid precursor protein," Free Radical Biology and Medicine, vol. 48, no. 9, pp. 1236–1241, 2010.

[25] I. Peters, U. Igbavboa, T. Schütt et al., "The interaction of beta-amylloid protein with cellular membranes stimulates its own production," Biochimica et Biophysica Acta, vol. 1788, no. 5, pp. 964–972, 2009.

[26] G. P. Eckert, S. Chang, J. Eckmann et al., "Liposome-incorporated DHA increases neuronal survival by enhancing non-amyloidogenic APP processing," Biochimica et Biophysica Acta, vol. 1808, no. 1, pp. 236–243, 2011.

[27] S. L. Bernstein, T. Wytenbach, A. Baumketter et al., "Amyloid β-protein: monomer structure and early aggregation states of Aβ42 and its Pro alloform," Journal of the American Chemical Society, vol. 127, no. 7, pp. 2075–2084, 2005.

[28] R. Friedman, R. Pellarin, and A. Calìsh, "Amyloid Aggregation on Lipid Bilayers and Its Impact on Membrane Permeability," Journal of Molecular Biology, vol. 387, no. 2, pp. 407–415, 2009.

[29] A. Kakio, S. I. Nishimoto, K. Yanagisawa, Y. Kozutsumi, and K. Matsuzaki, "Interactions of amyloid β-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid," Biochemistry, vol. 41, no. 23, pp. 7385–7390, 2002.

[30] E. Terzi, G. Hölzemann, and J. Seelig, "Interaction of Alzheimer β-amyloid peptide(1-40) with lipid membranes," Biochemistry, vol. 36, no. 48, pp. 14845–14852, 1997.

[31] Y. Sokolov, J. A. Kozak, R. Kayed, A. Chanturiya, C. Glahe, and J. E. Hall, "Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure," Journal of General Physiology, vol. 128, no. 6, pp. 637–647, 2006.

[32] A. Buchsteiner, T. Hauß, S. Dante, and N. A. Dencher, "Alzheimer’s disease amyloid-β peptide analogue alters the ps-dynamics of phospholipid membranes," Biochimica et Biophysica Acta, vol. 1798, no. 10, pp. 1969–1976, 2010.

[33] G. P. Eckert, W. G. Wood, and W. E. Müller, "Lipid membranes and β-amyloid: a harmful connection," Current Protein and Peptide Science, vol. 11, no. 5, pp. 319–325, 2010.

[34] P. T. Wong, J. A. Schauerte, K. C. Wirser et al., "Amyloid-β membrane binding and permeabilization are distinct processes influenced separately by membrane charge and fluidity," Journal of Molecular Biology, vol. 386, no. 1, pp. 81–96, 2009.

[35] T. L. Lau, E. E. Ambroggio, D. J. Twe et al., "Amyloid-β peptide disruption of lipid membranes and the effect of metal ions," Journal of Molecular Biology, vol. 356, no. 3, pp. 759–770, 2006.

[36] T. L. Lau, J. D. Gehman, J. D. Wade et al., "Membrane interactions and the effect of metal ions of the amyloidogenic fragment Aβ(25-35) in comparison to Aβ(1-42)," Biochimica et Biophysica Acta, vol. 1768, no. 10, pp. 2400–2408, 2007.

[37] J. McLaurin, D. S. Yang, C. M. Yip, and P. E. Fraser, "Review: modulating factors in amyloid-β fibril formation," Journal of Structural Biology, vol. 130, no. 2-3, pp. 259–270, 2000.

[38] M. Vestergaard, T. Hamada, and M. Takagi, "Using model membranes for the study of amyloid beta:lipid interactions and neurotoxicity," Biotechnology and Bioengineering, vol. 99, no. 4, pp. 753–763, 2008.

[39] K. Matsuoka, "Physicochemical interactions of amyloid β-peptide with lipid bilayers," Biochimica et Biophysica Acta, vol. 1768, no. 8, pp. 1935–1942, 2007.

[40] Y. Verdier, M. Zarándi, and B. Penke, "Amyloid β-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer’s disease," Journal of Peptide Science, vol. 10, no. 5, pp. 229–248, 2004.

[41] G. P. Eckert, "Manipulation of lipid rafts in neuronal cells," The Open Biology Journal, vol. 3, pp. 1874–1967, 2010.

[42] U. Igbavboa, N. A. Avdulov, F. Schroeder, and W. G. Wood, "Increasing age alters transblayer fluidity and cholesterol asymmetry in synaptic plasma membranes of mice," Journal of Neurochemistry, vol. 66, no. 4, pp. 1717–1725, 1996.

[43] Y. Barenholz, "Sphingomyelin and cholesterol: from membrane biophysics and rafts to potential medical applications," Sub-cellular Biochemistry, vol. 37, pp. 167–215, 2004.

[44] W. G. Wood, F. Schroeder, U. Igbavboa, N. A. Avdulov, and S. V. Chochina, "Brain membrane cholesterol domains, aging and amyloid beta-peptides," Neurobiology of Aging, vol. 23, no. 5, pp. 685–694, 2002.

[45] D. Arras and J. Martins, "Bilayer polarity and its thermal dependency in the, and lθ phases of binary phosphatidylcholine/cholesterol mixtures," Biochimica et Biophysica Acta, vol. 1768, no. 11, pp. 2914–2922, 2007.

[46] Q. Chen, J. Amaral, P. Biancini, and J. Behar, "Excess membrane cholesterol alters human gallbladder muscle contractility and membrane fluidity," Gastroenterology, vol. 116, no. 3, pp. 678–685, 1999.

[47] K. K. Halling, B. Ramstedt, and J. P. Slette, "Glycosylation induces shifts in the lateral distribution of cholesterol from ordered towards less ordered domains," Biochimica et Biophysica Acta, vol. 1778, no. 4, pp. 1100–1111, 2008.

[48] D. Dumais, V. Latger, M. L. Viriot, W. Blondel, and J. F. Stoltz, "Membrane fluidity and oxygen diffusion in cholesterol-enriched endothelial cells," Clinical Hemorheology and Microcirculation, vol. 21, no. 3-4, pp. 255–261, 1999.
effects on membrane phase transition, fluidity, polarity and anisotropy," *Chemistry and Physics of Lipids*, vol. 106, no. 1, pp. 79–88, 2000.

[50] D. Wang and B. G. Schreurs, "Dietary cholesterol modulates the excitability of rabbit hippocampal CA1 pyramidal neurons," *Neuroscience Letters*, vol. 479, no. 3, pp. 327–331, 2010.

[51] M. Hao, S. Mukherjee, Y. Sun, and F. R. Maxfield, "Effects of cholesterol depletion and increased lipid unsaturation on the properties of endocytic membranes," *The Journal of Biological Chemistry*, vol. 279, no. 14, pp. 14171–14178, 2004.

[52] M. P. Burns and G. W. Rebeck, "Intracellular cholesterol homeostasis and amyloid precursor protein processing," *Biochimica et Biophysica Acta*, vol. 1801, no. 8, pp. 853–859, 2010.

[53] G. P. Eckert, C. Kirsch, and W. E. Müller, "Brain-membrane cholesterol in Alzheimer's disease," *Journal of Nutrition, Health and Aging*, vol. 7, no. 1, pp. 18–23, 2003.

[54] M. Kosieck, M. Malnar, A. Goate, and S. Heclimovic, "Cholesterol accumulation in Niemann Pick type C (NPC) model cells causes a shift in APP localization to lipid rafts," *Biochemical and Biophysical Research Communications*, vol. 393, no. 3, pp. 404–409, 2010.

[55] J. Xiu, A. Nordberg, X. Qi, and Z.-Z. Guan, "Influence of cholesterol and lovastatin on α-form of secreted amyloid precursor protein and expression of α7 nicotinic receptor on astrocytes," *Neurochemistry International*, vol. 49, no. 5, pp. 459–465, 2006.

[56] J. L. Galbete, T. R. Martin, E. Peressini, P. Modena, R. Bianchi, and G. Forloni, "Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway," *Biochemical Journal*, vol. 348, no. 2, pp. 307–313, 2000.

[57] M. Racchi, R. Baetta, N. Salvietti et al., "Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content," *Biochemical Journal*, vol. 322, no. 3, pp. 893–898, 1997.

[58] W. W. Liu, S. Todd, D. T. R. Coulson et al., "A novel reciprocal and biphasic relationship between membrane cholesterol and β-secretase activity in SH-SY5Y cells and in human platelets," *Journal of Neurochemistry*, vol. 108, no. 2, pp. 341–349, 2009.

[59] W. Davis, "The cholesterol transport inhibitor U18666a regulates amyloid precursor protein metabolism and trafficking in N2aAPP "swedish" cells," *Current Alzheimer Research*, vol. 5, no. 5, pp. 448–456, 2008.

[60] H. Runz, J. Riedtorf, I. Tomic et al., "Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells," *Journal of Neuroscience*, vol. 22, no. 5, pp. 1679–1689, 2002.

[61] H. J. Huttunen, C. Peach, R. Bhattacharyya et al., "Inhibition of acyl-coenzyme A: cholesterol acyltransferase modulates amyloid precursor protein trafficking in the early secretory pathway," *FASEB Journal*, vol. 23, no. 11, pp. 3819–3828, 2009.

[62] H. J. Huttunen, D. Havas, C. Peach et al., "The Acyl-coenzyme A: cholesterol acyltransferase inhibitor ci-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice," *Journal of Neuropathology and Experimental Neurology*, vol. 69, no. 8, pp. 777–788, 2010.

[63] L. Puglielli, B. C. Ellis, L. A. Mackenzie Ingano, and D. M. Kovacs, "Role of acyl-coenzyme A: cholesterol acyltransferase activity in the processing of the amyloid precursor protein," *Journal of Molecular Neuroscience*, vol. 24, no. 1, pp. 93–96, 2004.

[64] K. Fassbender, M. Simons, C. Bergmann et al., "Simvastatin strongly reduces levels of Alzheimer’s disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 10, pp. 5856–5861, 2001.

[65] J. Abad-Rodriguez, M. D. Ledesma, K. Craessaerts et al., "Neuronal membrane cholesterol loss enhances amyloid peptide generation," *Journal of Cell Biology*, vol. 167, no. 5, pp. 953–960, 2004.

[66] O. G. Lunev, N. A. Braze, N. V. Maksimova et al., "Ion transport, membrane fluidity and haemoglobin conformation in erythrocytes from patients with cardiovascular diseases: role of augmented plasma cholesterol," *Pathophysiology*, vol. 14, no. 1, pp. 41–46, 2007.

[67] M. M. Gleason, S. M. Medow, and T. N. Tilenko, "Excess membrane cholesterol alters calcium movements, cytosolic calcium levels, and membrane fluidity in arterial smooth muscle cells," *Circulation Research*, vol. 69, no. 1, pp. 216–227, 1991.

[68] A. Colell, C. Garcia-Ruiz, J. M. Lluis, O. Coll, M. Mari, and J. C. Fernández-Checa, "Cholesterol impairs the adenine nucleotide translocator-mediated mitochondrial permeability transition through altered membrane fluidity," *The Journal of Biological Chemistry*, vol. 278, no. 36, pp. 33928–33935, 2003.

[69] T. Rög, L. M. Stimson, M. Pasenkiewicz-Gierula, I. Vatutainen, and M. Karttunen, "Replacing the cholesterol hydroxyl group with the ketone group facilitates sterol flip-flop and promotes membrane fluidity," *Proceedings of Physical Chemistry B*, vol. 112, no. 7, pp. 1946–1952, 2008.

[70] M. G. Buffone, S. V. Verstraeten, J. C. Calamera, and G. F. Doncel, "High cholesterol content and decreased membrane fluidity in human spermatozoa are associated with protein tyrosine phosphorylation and functional deficiencies," *Journal of Andrology*, vol. 30, no. 5, pp. 552–558, 2009.

[71] M. Hashimoto, S. Hossain, and O. Shido, "Docosahexaenoic acid but not eicosapentaenoic acid withstands dietary cholesterol-induced decreases in platelet membrane fluidity," *Molecular and Cellular Biochemistry*, vol. 293, no. 1–2, pp. 1–8, 2006.

[72] S. Bodovitz and W. L. Klein, "Cholesterol modulates α-secretase cleavage of amyloid precursor protein," *The Journal of Biological Chemistry*, vol. 271, no. 8, pp. 4436–4440, 1996.

[73] J. R. Cirrito, J. E. Kang, J. Lee et al., "Endocytosis is required for synaptic activity-dependent release of amyloid-β in vivo," *Neuron*, vol. 58, no. 1, pp. 42–51, 2008.

[74] A. Kinoshita, H. Fukumoto, T. Shah, M. C. Whelan, M. C. Irizarry, and B. T. Hyman, "Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes," *Journal of Cell Science*, vol. 116, no. 16, pp. 3339–3346, 2003.

[75] L. Rajendran, A. Schneider, G. Schlechtingen et al., "Efficient inhibition of the Alzheimer’s disease β-secretase by membrane targeting," *Science*, vol. 320, no. 5875, pp. 520–523, 2008.

[76] S. Schöbel, S. Neumann, M. Hertweck et al., "A novel sorting nexin modules endocytic trafficking and α-secretase cleavage of the amyloid precursor protein," *The Journal of Biological Chemistry*, vol. 283, no. 21, pp. 14257–14268, 2008.

[77] S. A. Small and S. Gandy, "Sorting through the cell biology of Alzheimer’s disease: intracellular pathways to pathogenesis," *Neuron*, vol. 52, no. 1, pp. 15–31, 2006.

[78] O. M. Grbovic, P. M. Mathews, Y. Jiang et al., "Rab5-stimulated up-regulation of the endocytic pathway increases
in intracellular β-cleaved amyloid precursor protein carboxy-terminal fragment levels and Aβ production,” The Journal of Biological Chemistry, vol. 278, no. 33, pp. 31261–31268, 2003.

[79] J. C. Cossec, A. Simon, C. Marquer et al., “Clathrin-dependent APP endocytosis and Aβ secretion are highly sensitive to the level of plasma membrane cholesterol,” Biochimica et Biophysica Acta, vol. 1801, no. 8, pp. 846–852, 2010.

[80] J. P. Schuchardt, M. Huss, M. Stauss-Grabo, and A. Hahn, “Significance of long-chain polyunsaturated fatty acids (PUFAs) for the development and behaviour of children,” European Journal of Pediatrics, vol. 169, no. 2, pp. 149–164, 2010.

[81] C. K. Chow, Ed., Fatty Acids in Foods and Their Health Implications, Taylor & Francis, Boca Raton, Fla, USA, 2007.

[82] W. E. Connor, “Importance of n-3 fatty acids in health and disease,” American Journal of Clinical Nutrition, vol. 71, no. 1, pp. 1715–1755, 2000.

[83] S. C. Dyall and A. T. Michael-Titus, “Neurological benefits of omega-3 fatty acids,” NeuroMolecular Medicine, vol. 10, no. 4, pp. 219–235, 2008.

[84] N. G. Bazan and B. L. Scott, “Dietary omega-3 fatty acids and accumulation of docosahexaenoic acid in rod photoreceptor cells of the retina and at synapses,” Upsala Journal of Medical Sciences, Supplement, no. 48, pp. 97–107, 1990.

[85] R. T. Holman, S. B. Johnson, and P. L. Ogburn, “Deficiency of essential fatty acids and membrane fluidity during pregnancy and lactation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 11, pp. 4835–4839, 1991.

[86] R. Uauy, D. R. Hoffman, P. Peirano, D. G. Birch, and E. E. Birch, “Essential fatty acids in visual and brain development,” Lipids, vol. 36, no. 9, pp. 885–895, 2001.

[87] J. M. Alessandri, P. Guesnet, S. Vancassel et al., “Polyunsaturated fatty acids in the central nervous system: evolution of concepts and nutritional implications throughout life,” Reproduction Nutrition Development, vol. 44, no. 6, pp. 509–538, 2004.

[88] I. Carrière, G. Abellan Van Kan, Y. Rolland, S. Gillette-Guyonnet, and B. Vellas, “PUFA for prevention and treatment of dementia!” Current Pharmaceutical Design, vol. 15, no. 36, pp. 4173–4185, 2009.

[89] L. A. Horrocks and A. A. Farooqui, “Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 70, no. 4, pp. 361–372, 2004.

[90] S. C. Heinrichs, “Dietary ω-3 fatty acid supplementation for optimizing neuronal structure and function,” Molecular Nutrition and Food Research, vol. 54, no. 4, pp. 447–456, 2010.

[91] W. A. Khan, G. C. Blobe, and Y. A. Hannun, “Arachidonic acid and free fatty acids as second messengers and the role of protein kinase C,” Cellular Signalling, vol. 7, no. 3, pp. 171–184, 1995.

[92] L. Zhou and A. Nilsson, “Sources of eicosanoid precursor fatty acid pools in tissues,” Journal of Lipid Research, vol. 42, no. 10, pp. 1512–1522, 2001.

[93] A. J. Sinclair, D. Beggi, M. Mathai, and R. S. Weisiger, “Omega-3 fatty acids and the brain: review of studies in depression,” Asia Pacific Journal of Clinical Nutrition, vol. 16, no. 1, supplement, pp. 391–397, 2007.

[94] J. R. Hibbels, J. C. Umhau, D. T. George, S. E. Shaof, M. Limonla, and N. Salem Jr., “Plasma total cholesterol concentrations do not predict cerebrospinal fluid neurotransmitter metabolites: Implications for the biophysical role of highly unsaturated fatty acids,” American Journal of Clinical Nutrition, vol. 71, no. 1, supplement, pp. 3315–3385, 2000.

[95] S. I. Rapoport, “Arachidonic acid and the brain,” Journal of Nutrition, vol. 138, no. 12, pp. 2515–2520, 2008.

[96] A. M. Tully, H. M. Roche, R. Doyle et al., “Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer’s disease: a case-control study,” British Journal of Nutrition, vol. 89, no. 4, pp. 483–489, 2003.

[97] E. J. Schaefer, V. Bongard, A. S. Beiser et al., “Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the framingham heart study,” Archives of Neurology, vol. 63, no. 11, pp. 1545–1550, 2006.

[98] F. Calon, G. P. Lim, T. Morihara et al., “Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer’s disease,” European Journal of Neuroscience, vol. 22, no. 3, pp. 617–626, 2005.

[99] Q. L. Ma, F. Yang, E. R. Rosario et al., “β-Amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin,” Journal of Neuroscience, vol. 29, no. 28, pp. 9078–9089, 2009.

[100] E. Rogaeva, Y. Meng, J. H. Lee et al., “The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease,” Nature Genetics, vol. 39, no. 2, pp. 168–177, 2007.

[101] Q. L. Ma, B. Teter, O. J. Ubeda et al., “Omega-3 fatty acid docosahexaenoic acid increases SorLA/LR11, a sorting protein with reduced expression in sporadic Alzheimer’s disease (AD): relevance to AD prevention,” Journal of Neuroscience, vol. 27, no. 52, pp. 14299–14307, 2007.

[102] C. R. Hooijmans, C. E. E. M. Van der Zee, P. J. Dederen et al., “DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APP/PS1 mice,” Neurobiology of Disease, vol. 33, no. 3, pp. 482–498, 2009.

[103] S. Pepe, “Dietary polyunsaturated fatty acids and age-related membrane changes in the heart,” Annals of the New York Academy of Sciences, vol. 1114, pp. 381–388, 2007.

[104] S. R. Shaikh and M. Edidin, “Polyunsaturated fatty acids, membrane organization, T’ cells, and antigen presentation,” American Journal of Clinical Nutrition, vol. 84, no. 6, pp. 1277–1289, 2006.

[105] S. R. Shaikh and M. Edidin, “Polyunsaturated fatty acids and membrane organization: elucidating mechanisms to balance immunotherapy and susceptibility to infection,” Chemistry and Physics of Lipids, vol. 153, no. 1, pp. 24–33, 2008.

[106] S. Yehuda, S. Rabinovitz, R. L. Carasso, and D. I. Mostofsky, “The role of polyunsaturated fatty acids in restoring the aging neuronal membrane,” Neurobiology of Aging, vol. 23, no. 5, pp. 843–853, 2002.

[107] W. Stillwell, S. R. Shaikh, M. Zerouga, R. Siddiqui, and S. R. Wassall, “Docosahexaenoic acid affects cell signaling by altering lipid rafts,” Reproduction Nutrition Development, vol. 45, no. 5, pp. 559–579, 2005.

[108] B. Aricha, I. Fishov, Z. Cohen et al., “Differences in membrane fluidity and fatty acid composition between phenotypic variants of Streptococcus pneumoniae,” Journal of Bacteriology, vol. 186, no. 14, pp. 4638–4644, 2004.
[109] A. A. Cader, D. A. Butterfield, B. A. Watkins, B. H. Chung, and B. Hennig, "Electron spin resonance studies of fatty acid-induced alterations in membrane fluidity in cultured endothelial cells," *International Journal of Biochemistry and Cell Biology*, vol. 27, no. 7, pp. 665–673, 1995.

[110] S. Kitagawa, K. Kotani, and F. Kametani, "Inhibitory mechanism of cis-polysaturated fatty acids on platelet aggregation: the relation with their effects on Ca**2+** mobilization, cyclic AMP levels and membrane fluidity," *Biochimica et Biophysica Acta*, vol. 1054, no. 1, pp. 114–118, 1990.

[111] N. Lothhagen, C. Härtig, and W. Babel, "Pseudomonas putida NCTC 10936 balances membrane fluidity in response to physical and chemical stress by changing the saturation degree and the Trans/cis ratio of fatty acids," *Bioscience, Biotechnology and Biochemistry*, vol. 68, no. 2, pp. 317–323, 2004.

[112] I. B. Zavodnik, A. Zaborowski, A. Niekurza, and M. Bryszewska, "Effect of free fatty acids on erythrocyte morphology and membrane fluidity," *Biochemistry and Molecular Biology International*, vol. 42, no. 1, pp. 123–133, 1997.

[113] X. Yang, W. Sheng, G. Y. Sun, and J. C.-M. Lee, "Effects of fatty acid unsaturation numbers on membrane fluidity and α-secretase-dependent amyloid precursor protein processing," *Neurochemistry International*, vol. 58, no. 3, pp. 321–329, 2011.

[114] T. Fukaya, T. Gondaira, Y. Kashiya et al., "Arachidonic acid preserves hippocampal neuron membrane fluidity in senescent rats," *Neurobiology of Aging*, vol. 28, no. 8, pp. 1179–1186, 2007.

[115] A. M. Dorrance, D. Graham, A. Dominiczak, and R. Fraser, "Inhibition of nitric oxide synthesis increases erythrocyte membrane fluidity and unsaturated fatty acid content," *American Journal of Hypertension*, vol. 13, no. 11, pp. 1194–1202, 2000.

[116] P. C. Calder, P. Yaqoob, D. J. Harvey, A. Watts, and E. A. Newsholme, "Incorporation of fatty acids by concanavalin A-stimulated lymphocytes and the effect on fatty acid composition and membrane fluidity," *Biochemical Journal*, vol. 300, no. 2, pp. 509–518, 1994.

[117] W. Stillwell and S. R. Wassall, "Docosahexaenoic acid: membrane properties of a unique fatty acid," *Chemistry and Physics of Lipids*, vol. 126, no. 1, pp. 1–27, 2003.

[118] H. Suzuki, S. J. Park, M. Tamura, and S. Ando, "Effect of the long-term feeding of dietary lipids on the learning ability, fatty acid composition of brain stem phospholipids and synaptic membrane fluidity in adult mice: a comparison of sardine oil diet with palm oil diet," *Mechanisms of Ageing and Development*, vol. 101, pp. 119–128, 1998.

[119] M. Oksman, H. Ivonen, E. Hogyes et al., "Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amylod accumulation in APP/PS1 transgenic mice," *Neurobiology of Disease*, vol. 23, no. 3, pp. 563–572, 2006.

[120] C. R. Hooijmans, F. Rutters, P. J. Dederen et al., "Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched Typical Western Diet (TWD)," *Neurobiology of Disease*, vol. 28, no. 1, pp. 16–29, 2007.

[121] G. P. Lim, F. Calon, T. Morihara et al., "A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model," *Journal of Neuroscience*, vol. 25, no. 12, pp. 3032–3040, 2005.

[122] C. Sahlin, F. E. Pettersson, L. N. G. Nilsson, L. Lannfelt, and A.-S. Johansson, "Docosahexaenoic acid stimulates non-amyloidogenic APP processing resulting in reduced Aβ levels in cellular models of Alzheimer’s disease," *European Journal of Neuroscience*, vol. 26, no. 4, pp. 882–889, 2007.

[123] Y. Liu, L. Yang, K. Conde-Knape, D. Beher, M. S. Shearman, and N. S. Shachter, "Fatty acids increase presenilin-1 levels and γ-secretase activity in PSwt-1 cells," *Journal of Lipid Research*, vol. 45, no. 12, pp. 2368–2376, 2004.

[124] D. Stephenson, K. Rash, B. Smaistig et al., "Cytosolic phospholipase A2A is induced in reactive glia following different forms of neurodegeneration," *Glia*, vol. 27, no. 2, pp. 110–128, 1999.

[125] D. T. Stephenson, C. A. Lemere, D. J. Selkoe, and J. A. Clemens, "Cytosolic phospholipase A (cPLA2) immunoreactivity is elevated in Alzheimer’s disease brain," *Neurobiology of Disease*, vol. 3, no. 1, pp. 51–63, 1996.

[126] G. S. D. Moses, M. D. Jensen, L. F. Lue et al., "Secretory PLA-IIA: a new inflammatory factor for Alzheimer’s disease," *Journal of Neuroinflammation*, vol. 3, article 28, 2006.

[127] R. M. Adibhatla and J. F. Hatcher, "Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia," *Free Radical Biology and Medicine*, vol. 40, no. 3, pp. 376–387, 2006.

[128] A. A. Farooqui, W.-Y. Ong, and L. A. Horrocks, "Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders," *Pharmacological Reviews*, vol. 58, no. 3, pp. 591–620, 2006.

[129] G. Y. Sun, L. A. Horrocks, and A. A. Farooqui, "The roles of NADPH oxidase and phospholipases A in oxidative and inflammatory responses in neurodegenerative diseases," *Journal of Neurochemistry*, vol. 103, no. 1, pp. 1–16, 2007.

[130] A. A. Farooqui and L. A. Horrocks, "Phospholipase A2A-generated lipid mediators in the brain: the good, the bad, and the ugly," *Neuroscientist*, vol. 12, no. 3, pp. 245–260, 2006.

[131] T. Yagami, "Cerebral arachidonate cascade in dementia: Alzheimer’s disease and vascular dementia," *Current Neuropsychopharmacology*, vol. 4, no. 1, pp. 87–100, 2006.

[132] S. Yedgar, Y. Cohen, and D. Shoseyov, "Control of phospholipase A2 activities for the treatment of inflammatory conditions," *Biochimica et Biophysica Acta*, vol. 1761, no. 11, pp. 1373–1382, 2006.

[133] E. A. Dennis, "Diversity of group types, regulation, and function of phospholipase A2," *The Journal of Biological Chemistry*, vol. 269, no. 18, pp. 13057–13060, 1994.

[134] M. Murakami and I. Kudo, "Phospholipase A2A," *Journal of Biochemistry*, vol. 131, no. 3, pp. 285–292, 2002.

[135] G. Y. Sun, J. Xu, M. D. Jensen, and A. Simonyi, "Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases," *Journal of Lipid Research*, vol. 45, no. 2, pp. 205–213, 2004.

[136] G. Y. Sun, J. Xu, M. D. Jensen et al., "Phospholipase A2 in astrocytes: responses to oxidative stress, inflammation, and G protein-coupled receptor agonists," *Molecular Neurobiology*, vol. 31, no. 1–3, pp. 27–41, 2005.

[137] V. Colangelo, J. Schurr, M. J. Ball, R. P. Pelaez, N. G. G. L. Watson, and W. J. Lukiw, "Gene expression profiling of apoptotic and pro-inflammatory signaling," *Journal of Neuroscience Research*, vol. 70, no. 3, pp. 462–473, 2002.

[138] R. O. Sanchez-Mejia, J. W. Newman, S. Toh et al., "Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer’s disease," *Nature Neuroscience*, vol. 11, no. 11, pp. 1311–1318, 2008.
[139] C. Bate and A. Williams, “Squalene protects neurons and reduces the activation of cytoplasmic phospholipase A by Aβ,” Neuropharmacology, vol. 53, no. 2, pp. 222–231, 2007.

[140] B. Kriem, I. Sponne, A. Firs et al., “Cytosolic phospholipase A mediates neuronal apoptosis induced by soluble oligomers of the amyloid-β peptide,” FASEB Journal, vol. 19, no. 1, pp. 85–87, 2005.

[141] M. Chalimoniuk, A. Stolecka, M. Cakala et al., “Amyloid beta enhances cytosolic phospholipase A level and arachidonic acid release via nitric oxide in APP-transfected PC12 cells,” Acta Biochimica Polonica, vol. 54, no. 3, pp. 611–623, 2007.

[142] P. B. Shelat, M. Chalimoniuk, J. H. Wang et al., “Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A in cortical neurons,” Journal of Neurochemistry, vol. 106, no. 1, pp. 45–55, 2008.

[143] S. Askarova and D. M. Lee, “Role of oligomeric Abeta-RAGE interaction in NADPH oxidase complex assembly and ROS production in astrocytes and cerebral endothelial cells,” unpublished data.

[144] W. F. Gattaz, O. V. Forlenza, L. L. Talib, N. R. Barbosa, and C. M. C. Bottino, “Platelet phospholipase A activity in Alzheimer’s disease and mild cognitive impairment,” Journal of Neural Transmission, vol. 111, no. 5, pp. 591–601, 2004.

[145] E. Krzyzanek, M. Krzyzanek, G. Opala, H. I. Trzeciak, J. Siuda, and A. Malecki, “Platelet phospholipase A activity in patients with Alzheimer’s disease, vascular dementia and ischemic stroke,” Journal of Neural Transmission, vol. 114, no. 8, pp. 1033–1039, 2007.

[146] W. F. Gattaz, A. Maras, N. J. Cairns, R. Levy, and H. Förstl, “Decreased phospholipase A activity in Alzheimer brains,” Biological Psychiatry, vol. 37, no. 1, pp. 13–17, 1995.

[147] J. B. Hicks, Y. Lai, W. Sheng et al., “Amyloid-β peptide induces temporal membrane biphasic changes in astrocytes through cytosolic phospholipase A,” Biochimica et Biophysica Acta, vol. 1778, no. 11, pp. 2512–2519, 2008.

[148] D. Zhu, C. Hu, W. Sheng et al., “NAD(P)H oxidase-mediated reactive oxygen species production alters astrocyte membrane molecular order via phospholipase A,” Biochemical Journal, vol. 421, no. 2, pp. 201–210, 2009.

[149] M. S. Liu, S. Ghosh, and Y. Yang, “Change in membrane lipid fluidity induced by phospholipase A activation: a mechanism of endotoxic shock,” Life Sciences, vol. 33, no. 20, pp. 1993–2002, 1983.

[150] E. L. Schaeffer, F. Bassi, and W. F. Gattaz, “Inhibition of phospholipase A activity reduces membrane fluidity in rat hippocampus,” Journal of Neural Transmission, vol. 112, no. 5, pp. 641–647, 2005.

[151] G. P. Eckert, N. J. Cairns, A. Maras, W. F. Gattaz, and W. E. Müller, “Cholesterol modulates the membrane-disordering effects of beta-amyloid peptides in the hippocampus: specific changes in Alzheimer’s disease,” Dementia and Geriatric Cognitive Disorders, vol. 11, no. 4, pp. 181–186, 2000.

[152] B. M. Ross, A. Moszczynska, J. Érlach, and S. J. Kish, “Phospholipid-metabolizing enzymes in Alzheimer’s disease: increased lysophospholipid acyltransferase activity and decreased phospholipase A activity,” Journal of Neurochemistry, vol. 70, no. 2, pp. 786–793, 1998.

[153] O. V. Forlenza, E. L. Schaeffer, and W. F. Gattaz, “The role of phospholipase A in neuronal homeostasis and memory formation: implications for the pathogenesis of Alzheimer’s disease,” Journal of Neural Transmission, vol. 114, no. 2, pp. 231–238, 2007.

[154] R. Beck, S. Bertolino, S. E. Abbot, P. I. Aaronson, and S. V. Smirkov, “Modulation of arachidonic acid release and membrane fluidity by albumin in vascular smooth muscle and endothelial cells,” Circulation Research, vol. 83, no. 9, pp. 923–931, 1998.

[155] A. Villacara, M. Spatz, R. F. Dodson, C. Corn, and J. Bembry, “Effect of arachidonic acid on cultured cerebrovascular endothelium: permeability, lipid peroxidation and membrane “fluidity,” Acta Neuropathologica, vol. 78, no. 3, pp. 310–316, 1989.

[156] X. Yang, W. Sheng, Y. He et al., “Secretory phospholipase A2 type II enhances α-secretase-dependent amyloid precursor protein processing through alterations in membrane fluidity,” Journal of Lipid Research, vol. 51, no. 5, pp. 957–966, 2010.

[157] D. Kögel, E. Copanaki, U. Hartig et al., “Modulation of membrane fluidity by omega 3 fatty acids: enhanced generation of sAPalpha is required for the neuroprotective effects of DHA,” in Proceedings of the 38th Annual Meeting of the Society for Neuroscience, 2008.

[158] I. V. J. Murray, M. E. Sindoni, and P. H. Axelsen, “Promotion of oxidative lipid membrane damage by amyloid β proteins,” Biochemistry, vol. 44, no. 37, pp. 12606–12613, 2005.

[159] J. K. Yao, T. M. Wengenack, G. L. Curran, and J. F. Poduslo, “Reduced membrane lipids in the cortex of Alzheimer’s disease transgenic mice,” Neurochemical Research, vol. 34, no. 1, pp. 102–108, 2009.

[160] R. Williamson, A. Usardi, D. P. Hanger, and B. H. Anderton, “Membrane-bound ß-amyloid oligomers are recruited into lipid rafts by a fyn-dependent mechanism,” FASEB Journal, vol. 22, no. 5, pp. 1552–1559, 2008.

[161] M. Bokvist, F. Lindström, A. Watts, and G. Gröbner, “Two types of Alzheimer’s β-amyloid (1-40) peptide membrane interactions: aggregation preventing transmembrane anchoring versus accelerated surface fibril formation,” Journal of Molecular Biology, vol. 335, no. 4, pp. 1039–1049, 2004.

[162] P. T. Lansbury Jr., “Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 7, pp. 3342–3344, 1999.

[163] S. Nag, J. Chen, J. Irudayaraj, and S. Maji, “Measurement of the attachment and assembly of small amyloid-β oligomers on live cell membranes at physiological concentrations using single-molecule tools,” Biophysical Journal, vol. 99, no. 6, pp. 1969–1975, 2010.

[164] H. Jang, J. Zheng, R. Lal, and N. Nussinov, “New structures help the modeling of toxic amyloid β ion channels,” Trends in Biochemical Sciences, vol. 33, no. 2, pp. 91–100, 2008.

[165] J. McLaurin and A. Chakrabarty, “Membrane disruption by Alzheimer β-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity,” The Journal of Biological Chemistry, vol. 271, no. 43, pp. 26482–26489, 1996.

[166] M. J. O. Widenbrant, J. Rajadas, C. Sutardja, and G. G. Fuller, “Lipid-induced membrane "fluidity" assembly on lipid bilayers,” Journal of Neurochemistry, vol. 78, no. 8, pp. 1051–1064, 2001.

[167] C. M. Yip, A. A. Darabie, and J. McLaurin, “Aβ42-peptide assembly on lipid bilayers,” Journal of Molecular Biology, vol. 318, no. 1, pp. 97–107, 2002.
